Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis to Report Second Quarter 2025 Financial Results on August 13
04:05pm, Wednesday, 30'th Jul 2025
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Codexis to Participate in Jefferies Global Healthcare Conference
04:05pm, Wednesday, 21'st May 2025
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript
06:50pm, Wednesday, 14'th May 2025
Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive O
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
06:40pm, Wednesday, 14'th May 2025
Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
Codexis Reports First Quarter 2025 Financial Results
04:05pm, Wednesday, 14'th May 2025
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcomin
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
07:00am, Wednesday, 07'th May 2025
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes
Codexis to Report First Quarter 2025 Financial Results on May 14
04:05pm, Wednesday, 30'th Apr 2025
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
11:09am, Thursday, 24'th Apr 2025
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis Announces Byron Dorgan to Retire from Board of Directors
05:00pm, Wednesday, 09'th Apr 2025
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced
Codexis Announces New Employment Inducement Grants
04:05pm, Friday, 07'th Mar 2025
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
10:20pm, Thursday, 27'th Feb 2025
Codexis, Inc. (NASDAQ:CDXS ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Execut
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
07:35pm, Thursday, 27'th Feb 2025
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.02 per share a year ago.
Codexis Announces New Employment Inducement Grants
05:15pm, Friday, 14'th Feb 2025
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
04:05pm, Thursday, 13'th Feb 2025
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
